Introduction: Bioanalytical Method Development for Oligonucleotide Therapeutics is the process of building and validating a quantitative assay that measures an […]
Introduction: MALDI-TOF mass spectrometry for peptide characterization is widely used to determine peptide molecular mass, support identity confirmation, and evaluate
Introduction PEGylated Peptide Characterization represents a comprehensive analytical framework designed to assess batch-to-batch consistency, chemical integrity, structural conformation, and purity
PEGylated Peptide Characterization: PEG Heterogeneity, Attachment Site and Purity Read More »
Introduction Non-enzymatic Deamidation and Aspartate Isomerization in Therapeutic Peptides are significant chemical degradation pathways that can modify peptide backbone structure,
Introduction Ion Mobility Mass Spectrometry enables the resolution of co-eluting isomeric peptide impurities by distinguishing gas-phase peptide ions according to
Ion Mobility Mass Spectrometry for Separating Isomeric Peptide Impurities Read More »
Introduction: Advanced analytical techniques for injectable drugs are the methods used to confirm the identity, strength, purity, safety, and quality
Advanced Analytical Techniques for Injectable Drugs Read More »
Introduction: Nitrosamine formation risk in drug products is an important quality and patient safety issue because certain nitrosamines are classified
Does Drug Product Formulation and pH Affect Nitrosamine Formation Risk? Read More »
Introduction: Peptide-oligonucleotide conjugates for oncology are engineered molecules in which a peptide is chemically linked to an oligonucleotide designed to
Peptide-Oligonucleotide Conjugates for Oncology Therapeutics Read More »
Introduction: PLGA Molecular Weight and End-Group Chemistry together determine how quickly a PLGA matrix hydrolyzes and how a drug moves
Introduction Contract Development and Manufacturing Organizations (CDMOs) implement ICH Q2(R2) and ICH Q14 as an integrated, lifecycle-oriented framework that brings
ICH Q2(R2) and ICH Q14: How CDMOs Apply the Analytical Procedure Lifecycle Read More »
